Who we are Cardio R&D Oncology R&D Careers News Contact Restoring Health through Complex Biology for Complicated Diseases At Salubris Biotherapeutics, Inc. (SalubrisBio)... We work to develop innovative and transformative therapeutic molecules which provide clinically meaningful improvements in disease burden and quality of life to patients with significant medical needs. What we do Salubris Biotherapeutics, Inc. (SalubrisBio) is a science-driven biotechnology company dedicated to the discovery and global development of novel antibody and protein-based therapeutics for the treatment of cancer and cardiovascular diseases. Our Research Focuses on oncology and cardiovascular disease. Together, these disease areas represent two of the most common causes of death in the world today. Oncology Cardiovascular Who we are We are a team brought together by our passion and commitment to excellence in drug discovery and development of novel therapies. Salubris Biotherapeutics, Inc © 2017-2020 | Privacy Policy | Terms & Conditions | site by Pierrot

Who we are Cardio R&D Oncology R&D Careers News Contact Mission At SalubrisBio we have passion, commitment, and enthusiasm for innovative drug discovery and development. We embrace challenges and value teamwork to solve problems and achieve our ambitions. We are the first company in the world to bring a bispecific antibody fusion protein into clinical trials in a cardiovascular indication. We endeavor to make this the first of many global innovation achievements. Who we are Sam Murphy Chief Executive Officer Sam Murphy Chief Executive Officer Sam has worked at Salubris for over four years – joining the company as VP and Head of International Business Development, and subsequently taking an additional role as Chief Business Officer. Prior to joining Salubris, Sam worked for more than ten years in strategy consulting and transaction advisory services across several global firms, most recently as a Senior Principal at IMS (now IQVIA). Sam’s commercial strategy engagements encompassed 18 of the top 25 pharmaceutical companies, as well as numerous small and mid-sized biotech companies, with an emphasis on business development and market access. Sam completed his PhD in Virology at the University of Pennsylvania and his Post-Doctoral Fellowship in Gene Therapy and Translational Medicine at Children’s Hospital of Philadelphia. Sam currently also serves as Chairman of the Board at GO Therapeutics, Board Director at MedAlliance SA and Viracta Therapeutics, and a Board Observer at Mercator Medsystems. He is an author of >20 peer-reviewed publications and an inventor on several issued patents. Research Focus We focus exclusively on the development of novel, complex biologic therapeutics which will provide clinically meaningful improvements in disease burden and quality of life to patients with significant medical needs. We work in the areas of cardiovascular disease and oncology. Together, these disease areas represent the two leading causes of death in the US today. US Leading Causes of Death (2017) Pipeline Overview Salubris Biotherapeutics, Inc © 2017-2020 | Privacy Policy | Terms & Conditions | site by Pierrot